Dr. Tejas Patil Joins ALKtALK 9/24/23

*This trial is currently available at the University of Colorado, University of Michigan, and Mass General. Patients DO NOT have to be local to participate in the trial.
*For more information regarding trial visits and opinions, please contact Charity Holien at [e-mail]
******
Tejas Patil, MD Assistant Professor, Medicine-Medical Oncology, University of Colorado, School of Medicine joined us on ALKtALK Sunday, September 24, 2023. View this recording to learn more about Dr. Patil's trial combining Amivantamab with an ALK TKI. This study is focused on assisting ALK-positive patients who have progressed on 2nd and 3rd generation TKI's without actionable mutations. Press PLAY to gain more information, options, and hope.

[@andreasmith3351]

Great watch for all ALK patients

[@prajendran8772]

Need finacial help for medicine

[@AbidAli-up6ve]

I'm on Lorlatinib for 4 years. Will I be eligible for trial

[@245nagore]

Hi can i talk to you, please reply